Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome.
about
Toll-like receptors: the swiss army knife of immunity and vaccine developmentImmune Adjuvant Effect of Molecularly-defined Toll-Like Receptor LigandsA potential protein adjuvant derived from Mycobacterium tuberculosis Rv0652 enhances dendritic cells-based tumor immunotherapy.The RTS,S vaccine candidate for malaria.Nasal immunity to staphylococcal toxic shock is controlled by the nasopharynx-associated lymphoid tissue.A Novel Class of Small Molecule Agonists with Preference for Human over Mouse TLR4 ActivationExamining the role of nasopharyngeal-associated lymphoreticular tissue (NALT) in mouse responses to vaccines.Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment.Phosphate substitution in an AlOOH - TLR4 adjuvant system (SPA08) modulates the immunogenicity of Serovar E MOMP from Chlamydia trachomatisEnhancement of serum and mucosal immune responses to a Haemophilus influenzae Type B vaccine by intranasal delivery.A rational, systematic approach for the development of vaccine formulations.Pattern recognition receptors in equine endotoxaemia and sepsis.Adjuvants containing natural and synthetic Toll-like receptor 4 ligands.E6020, a synthetic TLR4 agonist, accelerates myelin debris clearance, Schwann cell infiltration, and remyelination in the rat spinal cord.Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector.Molecular Modeling to Study Dendrimers for Biomedical Applications
P2860
Q26746644-6E74C20B-78A2-44A6-AFFC-81247B076BDCQ28972540-D1190E38-DCB9-40FE-9BC8-903BC08947E4Q34015759-A77FA648-FEF9-4F00-B8EC-CE386E9D93B9Q34186762-6F509705-144A-4F51-BAE3-E32D356260CBQ35066281-C1B04673-EC6F-4DC5-80FC-2E89AF20AA13Q36162709-5599E9F6-5E60-47EA-9FD6-DFDF11B5287EQ36334150-D706B0C7-4E29-429A-A60D-955E65254F6CQ36455017-D25E577A-CB4F-4D9C-A76F-6885D51109B3Q37264979-BF874DF3-3512-4913-85E2-984F3ADF573BQ37335477-A34709EC-217C-420D-AF61-98F984BABCCDQ37846559-B9C6785C-15D3-407A-8383-23B013614CAEQ38011228-00317EE5-D2B4-463C-B891-49767A715A6CQ38124063-59F7E922-1B8B-488C-8C4E-A02E516D2B81Q38934165-FDB36799-3037-454E-9C84-A35B69C1F654Q41644350-7ABE1167-5027-4C6C-9A54-A611C0E6C9DFQ42131157-CD42EDFA-3923-4FD3-92A8-4A087B50CB83Q59134583-B8916A42-13F4-4560-9568-3CC843584AD1
P2860
Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Synthetic Toll-like receptor 4 ...... model of toxic shock syndrome.
@ast
Synthetic Toll-like receptor 4 ...... model of toxic shock syndrome.
@en
type
label
Synthetic Toll-like receptor 4 ...... model of toxic shock syndrome.
@ast
Synthetic Toll-like receptor 4 ...... model of toxic shock syndrome.
@en
prefLabel
Synthetic Toll-like receptor 4 ...... model of toxic shock syndrome.
@ast
Synthetic Toll-like receptor 4 ...... model of toxic shock syndrome.
@en
P2093
P2860
P356
P1476
Synthetic Toll-like receptor 4 ...... model of toxic shock syndrome.
@en
P2093
Garry L Morefield
Lynn D Hawkins
Robert G Ulrich
Sally T Ishizaka
Teri L Kissner
P2860
P304
P356
10.1128/CVI.00153-07
P577
2007-08-22T00:00:00Z